Akademik Veri Yönetim Sistemi
Archives of Clinical and Experimental Medicine, cilt.6, sa.3, ss.100-103, 2021 (Hakemli Dergi)
Aim: Hemangioma is the most common benign tumor of the liver. They are rarely large, symptomatic, and show atypical imaging patterns. Surgical treatment indications are persistent symptoms, rapid size increase, lifethreatening complications, and diagnostic uncertainty. In this study, we aimed to present the results of our patients who underwent surgical treatment for persistent symptomatic hepatic hemangiomas regardless of size. Methods: We retrospectively evaluated the clinicodemographics, perioperative findings, and postoperative results of ten patients that we operated for symptomatic hepatic hemangiomas between 2017 and 2021. We made the diagnosis based on ultrasonography, computed tomography, and magnetic resonance imaging. Patients were evaluated in terms of age, gender, symptoms, tumor size and location, perioperative blood transfusion, operation time, postoperative complications, length of stay, and follow-up results. Results: The median age was 51 (25-60) and all of them were female. Although the persistent symptom in all patients was abdominal pain, we also had patients with additional symptoms such as dyspepsia and nausea. We performed enucleation in two, left lateral segmentectomy in one, right hepatectomy in two patients and, nonanatomical segmental resection in the rest. Perioperative blood transfusion was median 1 (0-3) unit and required in seven. The median operation time was 170 (135-230) minutes, and the median postoperative stay was 8.5 (4- 13) days. No serious complications developed in the postoperative period. The median follow-up time was 23.5 (9-40) months and, there was no recurrence or notable long-term complications. Conclusion: Surgical treatment can be performed safely and effectively in experienced centers for patients with symptomatic hepatic hemangioma.